Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 2/20 | 0.45 |
| ▸ | SLC6A7 | Q99884 | 3/20 | 0.43 |
| ▸ | C1S | P09871 | 2/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886830 | 0.90 | ALDH1A1 (0.42) | PARP14PARP10ALDH1A1TSHRUSP2 | |
| SCHEMBL5886817 | 0.90 | MGLL (0.36) | MGLLGBA1SLC6A7C1SALDH1A1 | |
| SCHEMBL5887197 | 0.90 | MAPT (0.44) | POLBALDH1A1MAPTMAPK1HTT | |
| SCHEMBL5887003 | 0.88 | CASP6 (0.38) | MGLLGBA1C1SALDH1A1MAPT | |
| SCHEMBL5886902 | 0.87 | GBA1 (0.46) | GBA1POLBALDH1A1TSHRMAPT | |
| SCHEMBL5887538 | 0.87 | RAB9A (0.51) | ALDH1A1TSHRMAPTMAPK1LMNA | |
| SCHEMBL5887184 | 0.86 | CHEK1 (0.46) | ALDH1A1TSHRUSP2MAPK1HTT | |
| SCHEMBL5887495 | 0.86 | MEN1 (0.46) | MGLLGBA1SLC6A7POLBMCHR1 | |
| SCHEMBL5886806 | 0.85 | ALDH1A1 (0.36) | MGLLALDH1A1TSHRUSP2MAPT | |
| SCHEMBL5886852 | 0.85 | LMNA (0.46) | ALDH1A1TSHRUSP2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | MGLL 4759/4885GBA1 4528/4885SLC6A7 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.